Heart Outcomes Prevention Evaluation

The HOPE Study (Heart Outcomes Prevention Evaluation) - PubMed

The Heart Outcomes Prevention Evaluation (HOPE) study was designed to test the hypotheses that two preventive intervention strategies, ...

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on ...

The double-blind, two-by-two factorial, randomized Heart Outcomes Prevention Evaluation study evaluated ramipril and vitamin E in 9541 patients.

Prevention of Heart Failure in Patients in the Heart Outcomes ...

The HOPE study was a double-blind, placebo-controlled, randomized trial with a two-by-two factorial design conducted to evaluate the effects of ...

The Heart Outcomes Prevention Evaluation Study - HOPE - Ramipril

The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60. The HOPE (Heart Outcomes Prevention Evaluation) ...

The Hope Study - Cleveland Clinic Journal of Medicine

The Heart Outcomes Prevention. Evaluation (HOPE) study found that the. ACE inhibitor ramipril can lower the risk of atherosclerotic disease events and.

Clinical, public health, and research implications of the Heart ...

S. Yusuf; Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study, European Heart Journal, Volume 22, I.

Heart Outcomes Prevention Evaluation–3 - HOPE-3

The HOPE-3 trial showed that fixed-dose treatment with low-dose statin therapy, but not BP agents, is superior to placebo in reducing long-term ...

the Heart Outcomes Prevention Evaluation (HOPE)-2 trial - PubMed

The patients' baseline characteristics confirmed their high-risk status. Baseline homocysteine levels varied between countries and regions. HOPE-2 is one of ...

The HOPE Study (Heart Outcomes Prevention Evaluation)

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients.

The Heart Outcomes Prevention Evaluation (HOPE) Study - Medscape

Overview. The Heart Outcomes Prevention Evaluation (HOPE) study was a landmark study employing the angiotensin-converting enzyme (ACE) inhibitor ramipril in a ...

Effects of ramipril on cardiovascular and microvascular outcomes in ...

3577 people with diabetes included in the Heart Outcomes Prevention Evaluation study, aged 55 years or older, who had a previous cardiovascular event or at ...

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on ...

This article has been corrected. VIEW THE CORRECTION. Author: The Heart Outcomes Prevention Evaluation Study InvestigatorsAuthor Info & ...

The HOPE (Heart Outcomes Prevention Evaluation) Study and its ...

The HOPE study was a 19 country, prospective randomized trial in which the ACE‐inhibitor Ramipril but not Vitamin E significantly reduced the ...

Heart Outcomes Prevention Evaluation (HOPE) Investigators: Effects ...

Kaplan-Meier curves show a significantly lower rate of each of the primary outcome endpoints in the ramipril group. The combined primary outcome relative risk ...

The striking effect of the Heart Outcomes Prevention Evaluation ...

HOPE led to a striking and unprecedented increase, over 400%, in ramipril prescribing to elderly Ontario residents, including those not eligible for the trial.

Heart Outcomes Prevention Evaluation (HOPE-3)

The Heart Outcomes Prevention Evaluation (HOPE-3) SOLARIS Study of Lipid Modification and Blood Pressure Reduction in People at Average Risk trial will ...

The HOPE (Heart Outcomes Prevention Evaluation) Study and its ...

The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences Journal Articles ... heart failure but at high-risk of cardiovascular events. It ...

The HOPE Study (Heart Outcomes Prevention Evaluation)

The HOPE (Heart Outcome Prevention. Evaluation) study was designed to test the hypotheses that two preventative intervention strategies, namely. ACE inhibition ...

Heart Outcomes Prevention Evaluation Study – GPnotebook

designed to investigate the effects of taking an ACE inhibitor ramipril and/or vitamin E for at least 4 years, on a wide range of vascular ...

Prevention of Heart Failure in Patients in the Heart Outcomes ...

Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. J. Malcolm O. Arnold, MD, Salim Yusuf, MD ...